Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Clinical Trials in Brazil / NCT07023146
Enrolling by invitation Not applicable

Effects of Different Power Training Intensities in Older Adults

NCT07023146 · tracked via the Priya Life Science Brazil tracker
Phase
Not applicable
Started
2025-04-02
Last updated
2025-06-15

Condition(s) studied

Investigating the Effects of Power Training in the Elderly

Investigational drug(s) / intervention(s)

Moderate to high intensity (PTMH; 65-80% of 1-repetition maximum [1RM]) )low to moderate intensity (PTLM; 40-60% of 1-repetition maximum [1RM])

Moderate to high intensity (PTMH; 65-80% of 1-repetition maximum [1RM]) ): Power training performed at maximum velocity in the concentric phase with moderate to high intensity

low to moderate intensity (PTLM; 40-60% of 1-repetition maximum [1RM]): Power training performed at maximum velocity in the concentric phase with lower to moderate intensity

Study summary

Power (strength × velocity) is a crucial component for maintaining independence during aging. Therefore, investigating interventions aimed at improving this physical capacity is essential for this population. The aim of this study is to examine the effects of power training (PT) performed at low to moderate intensity (PTLM; 40-60% of 1-repetition maximum \[1RM\]) and moderate to high intensity (PTMH; 65-80% of 1RM) on muscle power, kinematic gait parameters, strength, muscle thickness, and functional performance in older adults. Participants will be randomly assigned to perform PTLM and PTMH. Data collection will occur before and after familiarization, as well as at weeks 8 and 16 of the training programs. Participants will undergo a series of tests in the following sequence: 1) muscle thickness and 1RM test; 2) muscle power, maximum voluntary contraction, and rate of force development; 3) functional performance. The primary analyses will be conducted on an intention-to-treat basis, comparing the effects of the interventions and groups over time. Generalized Estimating Equations (GEE) will be used, considering the factors of group (2 levels) and time (3 levels). Paired comparisons will be assessed using the Bonferroni post-hoc test to identify significant differences between groups and time points. All tests will be performed using JASP software (version 0.16.4.0), with statistical significance set at p \< 0.05 for all analyses.

Eligibility

Sex
ALL
Min age
60 Years
Max age
—
Healthy volunteers
Accepted
Inclusion criteria: * Age 60 years or older * No participation in regular and systematic resistance training in the last three months * No absolute or relative contraindications to exercise * No musculoskeletal injuries that could interfere with training and assessments Exclusion criteria: * Use of steroids, nutritional supplements, or ergogenic substances * Failure to complete all study phases * Failure to complete more than 80% of the training sessions (32 sessions)

Primary outcome measure(s)

Trial sites (1)

FacilityCityRegionStatus
Universidade Federal do Rio Grande do Sul (UFRGS) Porto Alegre Rio Grande do Sul

More Federal University of Rio Grande do Sul trials in Brazil

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07023146 on ClinicalTrials.gov ↗ ← All trials in Brazil